Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients

Recruiting now

Conditions studied: Lung Diseases

In brief

The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.

Key facts

Study ID

NCT06494033

Run by

University of Miami

People needed

100

Starts

2024-07-03

Expected to finish

2026-12-30

Last updated by the study team

2026-03-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients over 18 years of age
• Lung transplant candidates with positive CMV IgG
• Anticipated to receive a lung transplant (both double lung and single lung)

You may not qualify if…

• Negative CMV IgG prior transplant
• Pregnant or breastfeeding women
• HIV infected patients
• Combined organ (e.g., lung-heart, lung-kidney) transplant candidates

Where it is running

• University of Miami — Miami, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.